Implantable systems and methods for monitoring bnp levels, hf and mi
AssigneePacesetter, Inc.
InventorsAllen Keel, Steve Koh, Taraneh Ghaffari Farazi
Life of this patent
Estimating the term…
Loading patent…
AssigneePacesetter, Inc.
InventorsAllen Keel, Steve Koh, Taraneh Ghaffari Farazi
Estimating the term…
Methods for monitoring a patient's level of B-type natriuretic peptide (BNP), and implantable cardiac systems capable of performing such methods, are provided. A ventricle is paced for a period of time to provoke a ventricular evoked response, and a ventricular intracardiac electrogram (IEGM) indicative of the ventricular evoked response is obtained. Based on the ventricular IEGM, there is a determination of at least one ventricular evoked response metric (e.g., ventricular evoked response peak-to-peak amplitude, ventricular evoked response area and/or ventricular evoked response maximum slope), and the patient's level of BNP is monitored based on determined ventricular evoked response metric(s). Based on the monitored level's of BNP, the patients heart failure (HF) condition and/or risks and/or occurrences of certain events (e.g., an acute HF exacerbation and/or an acute myocardial infarction) can be monitored.
A method for monitoring a patient's level of B-type natriuretic peptide (BNP), for use by an implanted system including an implanted cardiac device and at least one implanted lead, the method comprising:
An implantable system for monitoring a patient's level of B-type natriuretic peptide (BNP), comprising:
A method for selecting a preferred ventricular pacing energy level, for use by an implanted system including an implanted cardiac device and at least one implanted lead, the method comprising:
Dependencies are inferred from the claim text.